. 2016 Sep 13;7(42):68909–68920. doi: 10.18632/oncotarget.11996

Table 2. Reproducibility of significantly stable REOs in normal samples measured by each of the platforms.

	Label	Normal sample size	Gene^#	Number of stable REOs	Number of overlaps	POG₁₂	POG₂₁	Consistency	P
Lung
Affymetrix	SetA	150	20283	197,546,446	190,118,028	0.9434	0.9519	0.9802	<1.0-16
	SetB	65		195,767,556
Illumina	SetA	58	23364	251,964,302	231,498,834	0.8906	0.9061	0.9694	<1.0-16
	SetB	24		247,667,868
Agilent	SetA	60	19596	181,534,752	151,185,241	0.7833	0.9105	0.9406	<1.0-16
	SetB	13		156,176,364
Colorectal
Affymetrix	SetA	52	20283	193,475,574	184,134,774	0.9136	0.9135	0.96	<1.0-16
	SetB	32		193,501,698
Illumina	SetA	40	17789	148,902,375	131,019,285	0.8048	0.8723	0.9147	<1.0-16
	SetB	38		137,385,589
Agilent	SetA	31	18583	145,935,881	121,390,845	0.8099	0.87	0.9736	<1.0-16
	SetB	23		135,855,195

Note:

denotes the number of genes of SetA and setB measured by a particular platform. POG12 (or POG21) denotes the percentage of the significantly stable gene pairs (FDR<0.01) detected from SetA (or SetB) that are consistently detected in SetB (or SetA). Consistency denotes the percentage of overlapped gene pairs that display the same REO patterns between SetA and SetB and P denotes the significance of the consistency.